文献速递小儿眼科与斜弱视

化学去神经术与切开手术治疗急性获得性共同性内斜视的比较:一项国际研究

A Comparison of Chemodnervation to Incisional Surgery for Acute, Acquired, Comitant Esotropia: An International Study.
PubMed 文献 · Am J Ophthalmol · 2024-03-04

这项国际多中心非随机对照研究比较了肉毒毒素注射(化学去神经术)与斜视手术治疗儿童急性获得性共同性内斜视的疗效,在倾向性匹配队列(n=98)中,6个月和12个月成功率无显著差异,但24个月时化学去神经组显著低于手术组(52% vs 86.4%,P=.015)。无论治疗方式如何,治疗延迟与6个月成功率降低相关。

要点

  • 倾向性匹配队列中,化学去神经组与手术组6个月成功率无显著差异(70.2% vs 79.6%,P=.2)。
  • 24个月时化学去神经组成功率显著低于手术组(52% vs 86.4%,P=.015)。
  • 无论治疗方式如何,治疗延迟与6个月成功率降低相关(成功组中位时间4.5个月 vs 失败组7.7个月,P<.001)。

核心结论

  • 在急性获得性共同性内斜视儿童中,化学去神经术后成功率在12个月内与手术相似,但24个月时较低。
  • 及时干预且无弱视者结局最佳,与治疗方式无关。

研究设计与样本

  • 国际多中心非随机对照研究,采用云端问卷调查,纳入2至17岁因急性获得性共同性内斜视接受单次手术干预的儿童。
  • 共19个中心的术者参与,化学去神经组74例,手术组97例;倾向性匹配数据n=98。

主要发现

  • 倾向性匹配数据中,6个月成功率化学去神经组70.2% vs 手术组79.6%(P=.2),12个月62.9% vs 77.8%(P=.2),均无显著差异。
  • 24个月成功率化学去神经组52% vs 手术组86.4%(P=.015),化学去神经组显著低于手术组。
  • 无论治疗方式,治疗延迟与6个月成功率降低相关:成功组从发病到干预的中位时间4.5个月(IQR 2.1, 6.7),失败组7.7个月(IQR 5.6, 10.1),P<.001。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the efficacy of botulinum toxin injections to strabismus surgery in children with acute, acquired, comitant esotropia (ACE), and to investigate factors predicting success. DESIGN: International, multi-center nonrandomized comparative study METHODS: Setting: Cloud-based survey. STUDY POPULATION: Children aged 2 to 17 years who underwent a single surgical intervention for ACE. INTERVENTIONS: Botulinum toxin injection ("chemodenervation" group) or strabismus surgery ("surgery" group). MAIN OUTCOME MEASURES: Primary measure: success rate at 6 months in propensity-matched cohort, defined as total horizontal deviation of 10 prism diopters or less with evidence of binocular single vision. Secondary measure: Risk factors for poor outcomes in the full cohort. RESULTS: Surgeons from 19 centers contributed. There were 74 patients in the chemodenervation group and 97 patients in the surgery group. In the propensity-matched data (n = 98), success rate was not significantly different at 6 months (70.2% vs 79.6%; P = .2) and 12 months (62.9% vs 77.8%; P = .2), but was significantly lower in the chemodenervation group at 24 months (52% vs 86.4%; P = .015). Irrespective of treatment modality, treatment delay was associated with lower success rates at 6 months, with median time from onset to intervention 4.5 months (interquartile range (IQR): 2.1, 6.7) in the success group and 7.7 months (IQR: 5.6, 10.1) in the failure group (P < .001). CONCLUSIONS: In children with ACE, success rate after chemodenervation was similar to that of surgery for up to 12 months but lower at 24 months. Those with prompt intervention and no amblyopia had the most favorable outcomes, regardless of treatment modality.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Cheung CSY, Wan MJ, Zurakowski D, et al. A Comparison of Chemodnervation to Incisional Surgery for Acute, Acquired, Comitant Esotropia: An International Study. Am J Ophthalmol. 2024. PMID: 38447598. doi:10.1016/j.ajo.2024.02.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。